Quantum Molecular Resonance (QMR) Rehabiltative Treatment of Knee Osteoarthritis

Not Applicable

Completed

• Conditions: Knee Pain Chronic
• Interventions: Device: QMR

• Registration Number: NCT06239805
• Lead Sponsor: G. d'Annunzio University

Brief Summary

Gonarthrosis (osteoarthritis of the knee (OA) is a chronic-degenerative disease, characterized by progressive joint damage up to disability that affects about 40% of people over 65 years of age. Its typical pathological changes, articular cartilage degradation, synovial inflammation and subchondral bone thickening, are responsible for the pain and disability of patients. It is now known that "biophysical stimulation" techniques represent a non-invasive therapy used in orthopedic practice to enhance the reparative and anabolic activities of the tissues through an anti-inflammatory and chondro-protective effect.The aim of the study will be to evaluate the anti-inflammatory effects and the relative mechanisms of action of the therapeutic interventions of the QMR technology (Molecular Quantum Resonance) in the treatment of gonarthrosis through the use of in vivo and in vitro models. This technology, supplied by Telea Electronic Engineering s.r.l., exploits non-ionizing high-frequency waves in the range between 4 and 64 MHz at low intensity delivered through alternating electric fields. For the in vivo study, a double-blind randomized controlled clinical trial will be conducted. Both male and female subjects, aged between 40 and 80 years, with knee pain both in the acute and chronic phase of gonarthosis, diagnosed on standard radiography, will be enrolled. Patients will be randomized into 2 groups treated with an intensive or extensive protocol, and a third untreated control group. They will be evaluated at T0 (before treatment), at T1 (end of QMR treatment), and at T2 (one month after the end of treatment (follow-up)). All patients will be assessed for pain and functionality, furthermore synovial fluid and blood sampling will be performed, for the quantitative assessment of the inflammatory state considering the levels of the main pro-inflammatory cytokines and the pro/anti-inflammatory macrophage phenotype. In parallel, in order to delineate the molecular and cellular mechanism of action of QMR stimulation in vitro, a monocyte cell model (THP-1 cell line) will be used to evaluate the response of QMR treatment after treatment with known pro-inflammatory stimuli .

Detailed Description

For the in vivo study, a double-blind randomized controlled clinical trial will be conducted. Both male and female subjects, aged between 40 and 80 years, with knee pain both in the acute and chronic phase of gonarthosis, diagnosed on standard radiography, will be enrolled. Patients will be randomized into 2 groups treated with an intensive or extensive protocol, and a third untreated control group. They will be evaluated at T0 (before treatment), at T1 (end of QMR treatment), and at T2 (one month after the end of treatment (follow-up). All patients will be assessed for pain and functionality, furthermore synovial fluid and blood sampling will be performed, for the quantitative assessment of the inflammatory state considering the levels of the main pro-inflammatory cytokines and the pro/anti-inflammatory macrophage phenotype.

Study Timeline

• Study First Submitted: 2023-01-20
• Study Start: 2023-02-14
• Primary Completion: 2023-06-30
• Study Completion: 2023-11-30
• Status Verified: 2024-01
• Study First Submitted QC: 2024-01-25
• Last Update Submitted: 2024-01-25
• Study First Posted: 2024-02-02
• Last Update Posted: 2024-02-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Both male and female subjects, aged between 40 and 80 years, with knee pain both in acute and chronic phase due to gonarthosis diagnosed on standard radiography will be enrolled.

• Diagnosis of gonarthrosis with VAS >3
• Presence of acute or chronic pain (the sample will be stratified in one phase next)
• Radiographic picture of gonarthrosis and staging score according to Kellegren-Lawrence classification (I-II-III)

Exclusion Criteria

favism, hemolytic anemia

• severe hyperthyroidism - Graves' disease;
• drug treatment with Tapazole;
• thrombocytopenia less than 50,000 and serious coagulation disorders;
• severe cardiovascular instability;
• coagulation defects;
• alcohol abuse;
• hemochromatosis;
• patients being treated with food-nutraceutical supplements;
• pregnancy and bed rest;
• psychiatric pathologies;
• less than three months from previous knee infiltrations
• septic arthritis and/or febrile states
• anamnestic contraindications to the instrumental physical therapy in use (tumor pathologies past)

Furthermore, the following subjects will be excluded from the study:

• with rheumatic and autoimmune diseases
• patients with recent history of trauma and/or knee (ligament) sprain injuries

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental intensive group	QMR	Experimental: intensive treatment
Control extensive group	QMR	extensive treatment
control sham group	QMR	sham group

Primary Outcome Measures

Name	Time	Method
Knee pain	T2 - 1 mounth after the end of treatment	Visual Analogue Scale (VAS)

Secondary Outcome Measures

Name	Time	Method
Function	T2 - 1 mounth after the end of treatment	Knee injury and Osteoarthritis Outcome Score (KOOS-I); - Lysholm Knee Scoring Scale

Trial Locations

Locations (1)

Don Orione Foundation; 🇮🇹 Pescara, PE, Italy